SARC037: A Phase I Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with
a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a
Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI) National Institutes of Health (NIH)